Skip to main content
. 2022 Sep 20;3(9):100659. doi: 10.1016/j.xcrm.2022.100659

Figure 3.

Figure 3

Cabozantinib inhibits migration, invasion, and proliferation of HNSCC cells

(A) CAL33RR cells were treated with cabozantinib (5 μM) for 1 to 24 h. p-AXL, AXL, p-MET, MET, p-AKT, AKT, p-SRC, and SCR were evaluated by immunoblotting. Actin served as a loading control. N = 3.

(B) Serum-stimulated cell migration with cabozantinib (cabo) after 24 h was analyzed using Boyden chamber assays in 33, 33R, 33xR, and 33RR cells. Representative images are shown. N = 3.

(C) 33, 33R, 33xR, and 33RR cells were treated with cabozantinib (5 μM), and cell invasion was evaluated after 3 days using spheroid assays. Representative images are shown. N = 3. Statistics were performed using the ANOVA test: ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.